Octadecaneuropeptide Alleviates Motor and Cognitive Impairments in Neonatal Rats Following Hypoxic-Ischemic Brain Damage

J Mol Neurosci. 2022 Aug;72(8):1636-1645. doi: 10.1007/s12031-022-02022-w. Epub 2022 May 12.

Abstract

Hypoxic-ischemic brain damage (HIBD) is among the leading causes of neonatal brain injury. ODN, a peptide derived from diazepam-binding inhibitor (DBI), has potent antioxidant and anti-apoptotic properties. It remains unclear, however, whether ODN is an effective treatment for HIBD. Here, we reported that treatment with ODN (10 ng/day, i.c.v.) alleviated the deficits in myodynamia and motor coordination and cognitive functions in HIBD. Meanwhile, ODN prevented the neuronal loss in the cortex and hippocampus in HIBD rats. In addition, ODN decreased ROS by generating less oxidants and more antioxidants, as reflected by a dramatic increase in total antioxidant capacity, glutathione reductase, and catalase and a marked decrease in H2O2 and total nitric oxide synthase. Collectively, these data show ODN alleviates neuron injury and motor and memory deficits by attenuating ROS production and could be used as a novel molecular for treating HIBD.

Keywords: Cognition; Hypoxic-ischemic brain damage; ODN; Oxidative stress.

MeSH terms

  • Animals
  • Animals, Newborn
  • Antioxidants / pharmacology
  • Brain
  • Cognitive Dysfunction*
  • Diazepam Binding Inhibitor
  • Hydrogen Peroxide
  • Hypoxia-Ischemia, Brain* / drug therapy
  • Neuropeptides
  • Peptide Fragments
  • Rats
  • Reactive Oxygen Species

Substances

  • Antioxidants
  • Diazepam Binding Inhibitor
  • Neuropeptides
  • Peptide Fragments
  • Reactive Oxygen Species
  • diazepam binding inhibitor (33-50)
  • Hydrogen Peroxide